百特醫療 (BAX) 2025 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, ladies and gentlemen, and welcome to the Baxter International's fourth quarter 2025 earnings conference call. (Operator Instructions) As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time.

    女士們、先生們,早安,歡迎參加百特國際2025年第四季財報電話會議。(操作員說明)提醒您,本次通話由 Baxter 公司錄音,錄音內容受著作權保護。未經巴克斯特許可,不得錄製或重播。如有任何異議,請立即斷開連接。

  • I would now like to turn the call over to Mr. Kevin Moran, Vice President, Investor Relations at Baxter International. Mr. Moran, you may begin.

    現在我願將電話交給百特國際投資者關係副總裁凱文‧莫蘭先生。莫蘭先生,你可以開始了。

  • Kevin Moran - Investor Relations

    Kevin Moran - Investor Relations

  • Good morning, and welcome. Today, we will discuss Baxter's fourth quarter results, along with our financial outlook for the full year 2026. This morning, a press release was issued with our preliminary earnings results and updated outlook. The press release and investor presentation are available on the Investors section of the Baxter website.

    早安,歡迎。今天,我們將討論百特公司第四季的業績,以及我們對2026年全年的財務展望。今天上午,我們發布了一份新聞稿,其中包含了初步的獲利結果和更新後的展望。新聞稿和投資者簡報可在百特公司網站的投資者關係部分查閱。

  • Joining me today are Andrew Hider, President and Chief Executive Officer; and Joel Grade, Executive Vice President and Chief Financial Officer.

    今天與我一同出席的有總裁兼執行長安德魯·海德,以及執行副總裁兼財務長喬爾·格雷德。

  • During the call, we will be making forward-looking statements, including comments regarding our financial outlook for the full year 2026 and anticipated timing and impact of our deleveraging efforts. The amount and timing of charges related to recent operating model and cost structure actions, the anticipated impact of various regulatory and operational matters, including ones related to our infusion pump platform and to clinical practice changes following Hurricane Helene and commentary regarding the global macroeconomic environment, including tariffs and proposed mitigating actions.

    在電話會議期間,我們將發表前瞻性聲明,包括對我們 2026 年全年財務展望以及我們去槓桿化工作的預期時間和影響的評論。與近期營運模式和成本結構調整相關的費用金額和時間,各種監管和營運事項的預期影響(包括與我們的輸液泵平台相關的事項以及颶風海倫之後臨床實踐的變化),以及關於全球宏觀經濟環境(包括關稅和擬議的緩解措施)的評論。

  • Forward-looking statements involve risks and uncertainties, which could cause our actual results to differ materially from our current expectations. Please refer to today's press release, the forward-looking statement slide at the beginning of our investor presentation and our SEC filings for more detail.

    前瞻性陳述涉及風險和不確定性,可能導致我們的實際結果與我們目前的預期有重大差異。更多詳情請參閱今天的新聞稿、投資者簡報開頭的前瞻性聲明幻燈片以及我們向美國證券交易委員會提交的文件。

  • In addition, please note that on today's call, all our comments will be on a non-GAAP basis unless they are specifically called out as GAAP. Non-GAAP financial measures are used to help investors understand Baxter's ongoing business performance. GAAP to non-GAAP reconciliations can be found in the schedules attached to our press release and our investor presentation.

    此外,請注意,在今天的電話會議上,除非特別註明是按照公認會計準則 (GAAP) 發表,否則我們所有的評論都將是按照非公認會計準則 (non-GAAP) 發表的。非GAAP財務指標用於幫助投資者了解百特公司持續的業務表現。GAAP 與非 GAAP 的調整表可在我們的新聞稿和投資者簡報所附的附表中找到。

  • On the call, we will reference operational growth, which excludes the impact of foreign exchange, MSA revenues from Vantive and the previously announced exit of IV solutions from China. We will also reference organic growth, which excludes the impact of foreign exchange, MSA revenues from Vantive and any impact from future business acquisitions or divestitures. We plan to utilize the organic growth measure going forward.

    在電話會議上,我們將提及營運成長,但不包括外匯影響、Vantive 的 MSA 收入以及先前宣布的 IV 解決方案退出中國市場。我們也會參考有機成長,其中不包括外匯影響、Vantive 的 MSA 收入以及未來業務收購或剝離的任何影響。我們計劃今後繼續採用有機成長措施。

  • Finally, as a reminder, continuing operations excludes Baxter's Kidney Care business, which is now reported as discontinued operations.

    最後提醒一下,持續經營業務不包括百特腎臟護理業務,該業務現已被列為終止經營業務。

  • With that, I'd like to turn the call over to Andrew.

    接下來,我想把電話交給安德魯。

  • Andrew Hider - Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director

    Andrew Hider - Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director

  • Thank you, Kevin, and good morning, everyone. Fourth quarter 2025 global sales from continuing operations totaled $3 billion and increased 8% on a reported basis and 3% on an operational basis. Total company adjusted earnings from continuing operations were $0.44 per diluted share. While the top line exceeded our expectations, adjusted EPS fell short. Joel will get into greater detail on the results, but there were a few areas that differed from our expectations we provided in October.

    謝謝你,凱文,大家早安。2025 年第四季全球持續經營業務銷售額總計 30 億美元,依報告基準成長 8%,依營運基準成長 3%。公司持續經營業務調整後總收益為每股攤薄收益 0.44 美元。雖然營收超出預期,但調整後每股盈餘卻未達預期。喬爾將更詳細地介紹結果,但其中一些方面與我們在 10 月提供的預期有所不同。

  • On top line, we saw a more modest net impact from Novum IQ large volume pump customer returns, which was favorable to results. While responses have varied in general, customers are waiting for additional clarity on the nature and timing of the additional corrections that we will look to deploy. Margins were pressured by both an unfavorable mix of sales as well as some nonrecurring items, including inventory adjustments. And finally, we saw a higher tax rate.

    從整體來看,Novum IQ 大容量幫浦客戶退貨帶來的淨影響較為溫和,這對業績有利。雖然各方反應不一,但客戶仍在等待我們進一步明確我們將要部署的額外修正措施的性質和時間安排。銷售組合不佳以及一些非經常性項目(包括庫存調整)都對利潤率造成了壓力。最後,我們看到了更高的稅率。

  • The results in the quarter are disappointing and underscore the work ahead to improve performance and execute more consistently. I stepped into this role in August with confidence in the potential of the business, given the central role Baxter plays in health care, but also with a practical sense of the hurdles before us.

    本季業績令人失望,凸顯了未來在提升業績和提高執行力方面需要付出更多努力。今年八月,我走馬上任,對公司的潛力充滿信心,因為百特在醫療保健領域扮演著核心角色,但我也務實地意識到我們面臨的種種挑戰。

  • As I've continued to visit our sites and engage directly with the team and customers, I've deepened my understanding of both the challenges and opportunities facing Baxter. We are in the early stages of a turnaround and have more work to do to deliver strategically, operationally and commercially and recognize that it will take time to implement real long-term solutions.

    隨著我不斷走訪我們的各個站點,並與團隊和客戶直接交流,我對百特公司面臨的挑戰和機會有了更深入的了解。我們正處於轉型初期,在策略、營運和商業方面還有更多工作要做,我們也意識到,實施真正的長期解決方案需要時間。

  • That said, there's a strong thesis on where we can take this business, and we saw some examples of this in the quarter's results. For example, the Advanced Surgery business capped off a great year with a strong quarter, growing 11% with contributions both across the portfolio and around the globe.

    也就是說,我們對這項業務的發展方向有著清晰的認識,並且從本季的業績中也看到了一些例證。例如,高級外科手術業務在經歷了輝煌的一年後,以強勁的季度業績為這一年畫上了圓滿的句號,增長了 11%,這得益於其業務組合和全球範圍內的業績增長。

  • And the Healthcare Systems & Technologies segment had another quarter of consistent performance, including a contribution from the recently launched Connex 360 monitor in the Front Line Care division. We are also preparing for the launch of the recently announced Dynamo Series stretcher, the latest innovation in our portfolio of smart beds, surfaces and connected care solutions.

    醫療保健系統與技術部門又一個季度保持了穩定的業績,其中包括一線護理部門最近推出的 Connex 360 監視器的貢獻。我們也正在為推出最近發布的 Dynamo 系列擔架做準備,這是我們智慧床、表面和互聯護理解決方案產品組合中的最新創新。

  • Innovation will be a critical element to our success, and we recognize the importance of bringing new innovation into the market. Accordingly, you should expect a heightened focus going forward and continued investment in R&D at or above historical levels. As I said during our last earnings call and reiterated last month, I am focused on three main priorities.

    創新是我們成功的關鍵因素,我們認識到將新的創新引入市場的重要性。因此,您可以預期未來研發投入將更加重視,並持續保持在或超越歷史水準。正如我在上次財報電話會議上所說,並在上個月重申的那樣,我目前專注於三個主要優先事項。

  • These are stabilizing the areas of the business that require increased focus, strengthening our balance sheet and driving a culture of continuous improvement and efficiency. We are moving with focus and urgency on each of these, and our teams are driving relentlessly to improve execution and performance across the enterprise. It is with this in mind that we have decided to hold off on our Investor Day.

    這些措施正在穩定公司需要重點關注的領域,增強我們的資產負債表,並推動持續改進和提高效率的企業文化。我們正集中精力、加快步伐推進每一項工作,我們的團隊也在不懈地努力,以提高整個企業的執行力和績效。正是考慮到這一點,我們決定推遲投資者日活動。

  • Let me share a few updates on our priorities and the actions we have taken. Stabilize, just a few weeks ago, we internally announced a new operating model that is designed to simplify our organization, accelerate innovation and improve performance.

    讓我和大家分享我們工作重點和已採取的行動的最新進展。Stabilize,就在幾週前,我們內部宣布了一項新的營運模式,旨在簡化我們的組織,加速創新並提高績效。

  • Most significantly, we are delayering levers of leadership, including removing the segment management layer and embedding critical functional roles directly in each of our businesses. This will allow each leader to have full P&L responsibility for their business with fully aligned commercial, R&D, manufacturing, medical and targeted functional support and importantly, full accountability to the results.

    最重要的是,我們正在簡化領導層級,包括取消部門管理階層,並將關鍵職能角色直接嵌入我們每個業務部門。這將使每位領導者都能對其業務的損益負全責,並獲得完全協調一致的商業、研發、製造、醫療和目標職能支持,更重要的是,對結果負全責。

  • These changes are significant and are designed to reduce complexity, eliminate barriers for decision-making, bringing us closer to our customers and help us to improve our say-do ratio. We've also taken actions within our IV Solutions business to rightsize the support footprint to align to the lower demand environment, which we believe is a new baseline in the market.

    這些變化意義重大,旨在降低複雜性,消除決策障礙,拉近與客戶的距離,並幫助我們提高言行比。我們也採取了靜脈輸液解決方案業務方面的措施,調整支援規模,以適應較低的需求環境,我們認為這是市場上的新基準。

  • In pharma, in addition to market demand softness, supply and back order challenges have impacted revenue and driven unfavorable product mix. Specific initiatives to address these are in progress. However, it will take some time to bear fruit. Overall, across the enterprise, we are taking actions to further strengthen our focus on quality and improving on-time delivery, our two customer value creators.

    在製藥業,除了市場需求疲軟外,供應和缺貨挑戰也影響了收入,並導致了不利的產品組合。針對這些問題的具體措施正在進行中。然而,這需要一段時間才能見效。整體而言,在整個企業範圍內,我們正在採取措施,進一步加強對品質和準時交貨的關注,這是我們為客戶創造價值的兩大要素。

  • Balance sheet. We continue to focus on improving our cash generation and leverage. In line with our expectations, free cash flow generation exceeded $450 million in the quarter and continuous improvement. As a reminder, operational efficiency is at the center of what we are driving. As you know, a key element of this is our Baxter growth and performance system, Baxter GPS, which we rolled out in October to ensure continuous improvement, enterprise efficiency and a growth and performance mindset are integrated into our day-to-day work.

    資產負債表。我們將繼續專注於提高現金流和槓桿率。正如我們預期的那樣,本季自由現金流超過 4.5 億美元,並且持續改善。再次提醒大家,營運效率是我們工作的核心。如您所知,其中的關鍵要素是我們的 Baxter 成長和績效系統 Baxter GPS,我們於 10 月推出了該系統,以確保持續改進、企業效率以及成長和績效思維融入我們的日常工作中。

  • We recently held our first annual President's Kaizen, where I was impressed by the resolve each of our leaders demonstrated in driving change for the better with a focus on 10 events that will drive cross-business impact. Through focused week-long sprints, teams tackle critical opportunities aligned to our 8 value creators.

    我們最近舉辦了第一屆年度總裁改善大會,會上每位領導人都展現出了推動變革、力求更好的決心,這給我留下了深刻的印象。大會重點關注 10 項能夠產生跨業務影響的事件。透過為期一周的集中衝刺,團隊著手解決與我們的 8 個價值創造者相關的關鍵機會。

  • The work underway is helping us reduce complexity, better anticipate customer needs, accelerate innovation, commercialize faster and deliver value sooner. We are focused on improving every aspect of our operations, and we will be consistently measuring our performance to deliver just that. Importantly, this is not a one-off event. It's how we're building a continuous improvement culture where everyone is empowered to make things better every day.

    目前正在進行的工作有助於我們降低複雜性,更好地預測客戶需求,加速創新,更快地實現商業化,並更快地交付價值。我們致力於改善營運的各個方面,並將持續衡量我們的績效,以實現這一目標。重要的是,這並非一次性事件。這就是我們建構持續改善文化的方式,在這種文化中,每個人都有權利每天把事情做得更好。

  • Before I turn it over to Joel, I just wanted to reiterate the key steps we're taking. We have streamlined the organization for greater accountability. We have launched GPS to drive continuous improvement, and we have heightened our focus on innovation to better meet customer needs, all to drive improved performance and long-term shareholder value creation.

    在把麥克風交給喬爾之前,我只想重申我們正在採取的關鍵步驟。我們精簡了組織結構,以提高問責制。我們推出了 GPS 以推動持續改進,並更加重視創新以更好地滿足客戶需求,所有這些都是為了提高績效和創造長期股東價值。

  • Now I will turn it over to Joel. Joel, over to you.

    現在我把麥克風交給喬爾。喬爾,該你了。

  • Joel Grade - Executive Vice President and Chief Financial Officer

    Joel Grade - Executive Vice President and Chief Financial Officer

  • Thanks, Andrew, and good morning, everyone. Fourth quarter 2025 global sales from continuing operations totaled $3 billion and increased 8% on a reported basis and 3% on an operational basis. Performance in the quarter reflects growth across all segments. On the bottom line, total company adjusted earnings from continuing operations were $0.44 per share. Results in the quarter reflect unfavorable product and geographic mix, some nonrecurring items, including inventory adjustments and a higher tax rate, partially offset by the positive impact from pricing in select segments.

    謝謝你,安德魯,大家早安。2025 年第四季全球持續經營業務銷售額總計 30 億美元,依報告基準成長 8%,依營運基準成長 3%。本季業績反映了所有業務板塊的成長。最終,公司持續經營業務調整後的總收入為每股 0.44 美元。本季業績反映了不利的產品和地理組合、一些非經常性項目(包括庫存調整和較高的稅率),部分被特定細分市場定價帶來的正面影響所抵消。

  • Now I'll walk through our results by reportable segment. Commentary regarding sales growth in 2025 will be on an operational basis. Sales in our Medical Products & Therapies segments, or MPT, were $1.4 billion and increased 4% in the quarter. Performance in the quarter reflects growth in Infusion Therapies & Technologies or ITT as well as continued strength in Advanced Surgery.

    現在我將按可報告部分逐一介紹我們的業績。對 2025 年銷售成長的評論將以營運情況為基礎。我們的醫療產品和療法部門(簡稱 MPT)的銷售額為 14 億美元,本季成長了 4%。本季業績反映了輸液療法和技術(ITT)的成長,以及高階外科手術的持續強勁表現。

  • Within MPT, fourth quarter sales from our ITT division totaled $1.1 billion and grew 1%. Performance in the quarter was driven by growth in IV Solutions, which benefited from a favorable comparison in the prior year period, partially offset by lower infusion pump sales due to the previously discussed shipment and installation hold of Novum LVP.

    在 MPT 內部,我們 ITT 部門第四季的銷售額總計 11 億美元,成長了 1%。本季業績主要得益於 IV Solutions 的成長,這得益於去年同期良好的基數,但部分被輸液幫浦銷量下降所抵消,因為先前討論過的 Novum LVP 的出貨和安裝暫停了。

  • Within IV Solutions, underlying US demand remained below historical levels. As previously discussed, fluid conservation practices embedded with clinical practice changes in the market following Hurricane Helene remain and continue to weigh on volumes.

    在靜脈輸液解決方案領域,美國市場的潛在需求仍低於歷史水準。如前所述,颶風海倫過後,市場上的臨床實踐變化中融入了液體節約措施,這些措施仍然存在,並繼續對銷售造成影響。

  • In infusion systems, results in the quarter reflected the net impact of lost sales due to the ongoing shipment and installation hold of the Novum LVP, customer returns and transition to Spectrum. Relative to our prior guidance, this net impact was more modest in the quarter. While customer responses have varied, in general, many are understandably waiting for additional clarity on the nature and timing of additional corrections that we will look to deploy and of the release of the ship and installation hold.

    在輸液系統方面,本季業績反映了由於 Novum LVP 的持續發貨和安裝暫停、客戶退貨以及向 Spectrum 的過渡而造成的銷售損失的淨影響。與我們先前的預期相比,本季的淨影響更為溫和。雖然客戶的反應各不相同,但總的來說,許多客戶都在等待我們進一步明確我們將要部署的額外修正措施的性質和時間,以及解除船舶和安裝限制的時間,這完全可以理解。

  • Sales of Advanced Surgery totaled $328 million and grew an impressive 11%. Results in the quarter reflect continued solid demand for our portfolio of hemostats and sealants, strong commercial execution across regions and steady procedure volumes.

    高級外科手術的銷售額總計 3.28 億美元,成長了令人矚目的 11%。本季業績反映了市場對我們止血劑和密封劑產品組合的持續強勁需求、各地區的強勁商業執行力以及穩定的手術量。

  • MPT's adjusted operating margin totaled 15.4% for the quarter, decreasing 110 basis points over the prior year period and reflect increased manufacturing and supply costs, unfavorable product mix, inventory adjustments and higher costs related to tariffs. These factors were partially offset by positive pricing in the quarter. Kidney Care TSA income positively contributed as well.

    MPT 本季調整後的營業利潤率為 15.4%,比上年同期下降了 110 個基點,反映出製造和供應成本增加、產品組合不利、庫存調整以及與關稅相關的成本上升。本季積極的定價策略部分抵銷了這些不利因素。腎臟護理TSA收入也做出了積極貢獻。

  • In Healthcare Systems & Technologies, or HST, sales in the quarter totaled $827 million, increasing 4%. Within HST, sales of our Care & Connectivity Solutions, or CCS division were $537 million and grew 4% globally. Performance in the quarter was driven by double-digit growth in our Surgical Solutions business and continued momentum across our Patient Support Systems portfolio.

    在醫療保健系統與技術(HST)領域,本季銷售額總計 8.27 億美元,成長 4%。在 HST 內部,我們的 Care & Connectivity Solutions(簡稱 CCS)部門的銷售額為 5.37 億美元,全球成長了 4%。本季業績主要得益於外科解決方案業務的兩位數成長以及病患支援系統產品組合的持續成長動能。

  • Total US capital orders for CCS increased nearly 30% compared to the prior year, driven by broad-based strength across Patient Support Systems, care communications and Surgical Solutions, and our order book remains strong. To date, we have not observed a slowdown in US hospital capital spending. However, given the broader macroeconomic uncertainty, we continue to closely monitor the situation.

    與前一年相比,CCS 在美國的總資本訂單增長了近 30%,這主要得益於患者支持系統、護理溝通和外科解決方案的全面強勁表現,而且我們的訂單量依然保持強勁。迄今為止,我們尚未觀察到美國醫院資本支出放緩的跡象。然而,鑑於宏觀經濟情勢存在較大不確定性,我們將繼續密切關注事態發展。

  • Front Line Care sales in the quarter were $290 million and increased 3%. Performance in the quarter reflects increased demand in our cardiology and patient monitoring portfolios, which includes our recent launch of Connex 360.

    本季第一線護理銷售額為 2.9 億美元,成長 3%。本季業績反映了我們心臟病學和患者監測產品組合需求的成長,其中包括我們最近推出的 Connex 360。

  • HST adjusted operating margin totaled 15.2% for the quarter, decreasing 330 basis points compared to the prior year. These results reflect unfavorable product and geographic mix, increased corporate allocation expenses and higher costs related to tariffs. TSA income partially offset these increased expenses.

    本季經 HST 調整後的營業利益率為 15.2%,較上年同期下降 330 個基點。這些結果反映了不利的產品和地理組合、增加的企業分配費用以及與關稅相關的更高成本。TSA收入部分抵銷了這些增加的支出。

  • Moving on to our Pharmaceuticals segment. Sales in the quarter totaled $668 million, increasing 2%. Within Pharmaceuticals, sales of our Injectables & Anesthesia division were $352 million and declined 9%. Performance in the quarter reflects a decline in our injectables portfolio, driven by a difficult comparison to the prior year period as well as softness in certain premixed products, largely consistent with the dynamics discussed last quarter related to IV infusion protocols and increased use of IV push in select hospital settings.

    接下來是我們的藥廠。本季銷售額總計 6.68 億美元,成長 2%。在製藥業務方面,我們的注射劑和麻醉劑部門的銷售額為 3.52 億美元,下降了 9%。本季業績反映出我們的注射劑產品組合有所下滑,這是由於與上年同期相比比較困難,以及某些預混產品表現疲軟所致,這與上季度討論的靜脈輸液方案和在特定醫院環境中增加靜脈推注的使用情況基本一致。

  • Our anesthesia portfolio declined high single digits, reflecting softer demand for select inhaled anesthesia products. Drug Compounding grew 18% and reflects continued strong demand for our services outside the US, Pharmaceuticals adjusted operating margin totaled 5.8% for the quarter. These results reflect increased manufacturing and supply costs and unfavorable product mix, price erosion, inventory adjustments and increased corporate allocation expenses following the sale of Kidney Care. These expenses were partially offset by Kidney Care TSA income.

    我們的麻醉產品組合出現了接近兩位數的下滑,反映出部分吸入式麻醉產品的需求疲軟。藥物配製業務成長了 18%,反映出美國以外地區對我們服務的持續強勁需求;本季藥品業務調整後營業利潤率為 5.8%。這些結果反映了製造和供應成本增加、產品組合不利、價格下跌、庫存調整以及出售腎臟護理業務後公司分配費用增加等情況。這些支出部分被腎臟護理TSA收入抵銷。

  • Finally, other sales, which represent sales not allocated to a segment and primarily include sales of products and services provided directly through certain manufacturing facilities were $7 million in the quarter. MSA revenue from Vantive totaled $84 million. As a reminder, these sales are included in our reported growth. However, they are not reflected in our operational growth for the quarter.

    最後,本季其他銷售額為 700 萬美元,這部分銷售額未分配到任何業務部門,主要包括透過某些製造工廠直接提供的產品和服務的銷售額。來自 Vantive 的 MSA 收入總計 8,400 萬美元。再次提醒,這些銷售額已計入我們公佈的成長數據。然而,這些並未反映在我們本季的營運成長中。

  • Before moving on to the rest of the P&L, an important reminder on our continuing operations reporting. Following the sale of our Kidney Care business, certain corporate costs that did not convey with the business are now allocated across our segments in both cost of goods sold and SG&A, along with income from the TSA, which is currently recognized within other operating income.

    在繼續分析損益表的其餘部分之前,需要對我們的持續經營報告做一個重要的提醒。在我們出​​售腎臟護理業務後,某些未隨業務轉移的公司成本現在已分配到我們各個業務部門的銷售成本和銷售、一般及行政費用中,同時,來自 TSA 的收入目前已在其他營業收入中確認。

  • In addition, as previously discussed, we reclassified certain functional expenses from SG&A to cost of goods sold beginning earlier this year. These costs support manufacturing and are now treated as indirect expenses subject to inventory capitalization and recognized in cost of sales when sold.

    此外,正如之前討論過的,我們從今年年初開始將某些功能性費用從銷售、一般及行政費用重新分類到銷售成本中。這些成本用於支持生產製造,現在被視為間接費用,需進行存貨資本化,並在售出時計入銷售成本。

  • Fourth quarter adjusted gross margins from continuing operations were 35.5%, a decrease of 900 basis points compared to the prior year. Fourth quarter adjusted SG&A from continuing operations totaled $637 million or 21.4% as a percentage of sales, a decrease of 330 basis points from the prior year period. Results reflect disciplined expense management and the benefit from the reclassification of certain functional costs.

    第四季持續經營業務的調整後毛利率為 35.5%,較上年同期下降 900 個基點。第四季持續經營業務的調整後銷售、一般及行政費用總計 6.37 億美元,佔銷售額的 21.4%,比上年同期下降 330 個基點。結果反映了嚴格的費用管理以及對某些功能性成本進行重新分類所帶來的益處。

  • Adjusted R&D spending from continuing operations in the quarter totaled $116 million or 3.9% as a percentage of sales, which came in lower than our expectations. This reflects the reclassification of certain product support and sustaining activities into cost of sales and therefore, does not reflect our anticipated level of R&D spend going forward.

    本季持續經營業務的調整後研發支出總額為 1.16 億美元,佔銷售額的 3.9%,低於我們的預期。這反映了某些產品支援和維護活動被重新歸類為銷售成本,因此,並不反映我們未來預期的研發支出水準。

  • TSA income and other reimbursements totaled $50 million in the quarter and came in line with our expectations. As previously discussed, the associated expenses related to this income are reflected in other lines of the P&L, including cost of goods sold and SG&A.

    本季 TSA 收入和其他報銷總額為 5000 萬美元,符合我們的預期。如前所述,與此收入相關的費用反映在損益表的其他項目中,包括銷售成本及銷售、一般及行政費用。

  • Altogether, these factors resulted in an adjusted operating margin of 11.8% on a continuing operations basis, a decrease of 340 basis points compared to the prior year period. Results reflect unfavorable product mix and nonrecurring items, including inventory adjustments, partially offset by positive pricing in select segments and the benefits of TSA income.

    綜合這些因素,導致持續經營調整後的營業利潤率為 11.8%,比去年同期下降了 340 個基點。結果反映了不利的產品組合和非經常性項目(包括庫存調整),部分被特定細分市場的積極定價和 TSA 收入的收益所抵消。

  • Net interest expense from continuing operations totaled $58 million in the quarter, a decrease of $32 million versus the prior year period, reflecting lower interest expense following the paydown of existing debt with proceeds from the Vantive sale.

    本季持續經營業務的淨利息支出總計 5,800 萬美元,比上年同期減少了 3,200 萬美元,反映出在用 Vantive 出售所得償還現有債務後利息支出減少。

  • Adjusted other nonoperating income totaled $15 million, driven primarily by amortization of pension benefits compared to the prior period. The continuing operations adjusted tax rate for the quarter was 27.2%, driven primarily by mix of earnings across jurisdictions. In total, adjusted earnings from continuing operations were $0.44 per share for the quarter.

    經調整的其他非經營性收入總計 1,500 萬美元,主要原因是退休金福利攤銷較上期增加。本季持續經營調整後稅率為 27.2%,主要原因是不同司法管轄區的收益組成差異。本季持續經營業務調整後每股收益為 0.44 美元。

  • Before turning to our 2026 outlook, I want to comment on cash flow and liquidity. Fourth quarter free cash flow was $456 million, bringing full year free cash flow to $438 million. Performance in the quarter reflects improved cash flow generation and seasonality, including progress across select areas of working capital as well as continued focus on execution as we close out the year.

    在展望 2026 年之前,我想先談談現金流和流動性問題。第四季自由現金流為 4.56 億美元,全年自由現金流為 4.38 億美元。本季業績反映了現金流量產生和季節性因素的改善,包括營運資本特定領域的進展,以及在年底之際我們繼續專注於執行。

  • We continue to focus on strengthening cash flow generation and maintaining discipline around working capital foundational elements of our financial strategy. Improving the balance sheet continues to be a key area of emphasis, and we intend to deploy cash towards reducing leverage in line with our capital allocation framework.

    我們將繼續專注於強化現金流生成,並維持對營運資本此財務策略基礎要素的嚴格把控。改善資產負債表仍然是我們的重點工作領域,我們將按照資本配置框架,利用現金來降低槓桿率。

  • Now our outlook for the full year 2026, including some key assumptions underpinning the guidance. For full year 2026, we expect total sales growth to be flat to 1% growth on a reported basis. This reflects current foreign exchange rates, which are expected to contribute approximately 100 basis points to top line growth for the year.

    現在,我們展望 2026 年全年,其中包括支撐該指引的一些關鍵假設。我們預計 2026 年全年總銷售額成長將持平或成長 1%(以報告資料計算)。這反映了當前的匯率,預計匯率將為今年的營收成長貢獻約 100 個基點。

  • In addition, reported sales are expected to include a headwind of approximately $25 million from MSA revenues from Vantive. This represents approximately 30 basis points of impact on reported growth. Excluding the impact of foreign exchange and MSA revenues, we expect organic sales growth of approximately flat for 2026.

    此外,預計報告的銷售額將受到來自 Vantive 的 MSA 收入約 2500 萬美元的不利影響。這相當於對報告成長率產生了約 30 個基點的影響。不考慮外匯和MSA收入的影響,我們預計2026年有機銷售成長將基本持平。

  • As it relates to the segments, in MPT, we expect full year organic sales to be flat to slightly up. This reflects the continued uncertainty around the Novum situation, including the potential impact from various customer responses. It also reflects the assumption that the ship and installation hold will remain in place for the full year. And as previously discussed, we believe that the market is at a new baseline in our IV Solutions business. In HST, we expect full year organic sales to grow low single digits. This reflects expected contributions from both the Care & Connectivity Solutions and Front Line Care divisions.

    就各細分市場而言,在MPT領域,我們預期全年有機銷售額將持平或略有成長。這反映了 Novum 事件持續存在的不確定性,包括各種客戶反應可能帶來的影響。這也反映了船舶和安裝工程的停工將持續一整年的假設。如同先前討論過的,我們認為靜脈輸液業務的市場已經達到了一個新的基準線。在 HST,我們預計全年有機銷售額將實現個位數低成長。這反映了護理與連結解決方案部門和第一線護理部門的預期貢獻。

  • In Pharmaceuticals, we expect full year organic sales to be approximately flat. This reflects continued pressure in Injectables & Anesthesia related to softer market demand, supply challenges and ongoing IV push utilization trends that have been discussed in prior quarters.

    在製藥領域,我們預計全年有機銷售額將基本持平。這反映了注射劑和麻醉劑業務持續面臨的壓力,包括市場需求疲軟、供應挑戰以及前幾個季度討論過的持續靜脈推注使用趨勢。

  • Turning to our outlook for other P&L line items, beginning with tariffs. We estimate a full year impact net of mitigating actions to be approximately $80 million, which is a year-over-year headwind of approximately $40 million. TSA income and other reimbursements are expected to range between $130 million to $140 million.

    接下來,我們展望一下其他損益項目,首先是關稅。我們估計,扣除緩解措施後,全年淨影響約為 8,000 萬美元,比去年同期減少約 4,000 萬美元。美國運輸安全管理局預計收入和其他補償金額將在 1.3 億美元至 1.4 億美元之間。

  • We expect full year adjusted operating margin from continuing operations to range between 13% to 14%. This primarily reflects lower gross margins driven by unfavorable product mix, including the impact of lower manufacturing volumes and reduced contribution from pricing. These pressures are expected to be partially offset by improvements in SG&A, including the recent restructuring actions.

    我們預計全年持續經營業務的調整後營業利潤率將在 13% 至 14% 之間。這主要反映了由於產品組合不利(包括生產量減少和定價貢獻降低)導致的毛利率下降。這些壓力預計將部分被銷售、一般及行政費用的改善所抵消,包括最近的重組措施。

  • We expect our nonoperating expenses, which include net interest expense and other income and expense to total between $280 million to $300 million. This reflects higher interest expense from the recently completed debt-neutral transactions and lower contribution from other income. On a continuing operations basis, we anticipate a full year tax rate to range between 18.5% and 19.5%. We expect our diluted share count to average approximately 518 million shares for the year.

    我們預計非經營性支出(包括淨利息支出和其他收入和支出)總額將在 2.8 億美元至 3 億美元之間。這反映出近期完成的債務中性交易產生的利息支出較高,以及其他收入貢獻較低。依照持續經營原則,我們預計全年稅率將在 18.5% 至 19.5% 之間。我們預計全年稀釋後的平均股數約為 5.18 億股。

  • Based on all these factors, we now anticipate full year adjusted earnings on a continuing operations basis of $1.85 to $2.05 per diluted share. While we will not be providing explicit quarterly guidance, I want to offer some perspectives on the expected cadence of results over the course of the year.

    基於所有這些因素,我們現在預計全年持續經營調整後每股攤薄收益為 1.85 美元至 2.05 美元。雖然我們不會提供明確的季度業績指引,但我希望就全年業績的預期節奏提供一些看法。

  • Overall, we expect the first quarter to be the most challenging with improving performance thereafter. Specifically, the ITT division has an unfavorable year-over-year comparison in Q1 due to the onetime distributor build in the prior year.

    整體而言,我們預計第一季最具挑戰性,之後業績將逐步改善。具體來說,由於上一年一次性的經銷商建設,ITT 部門第一季的年比業績不利。

  • Additionally, ITT results in the first half are expected to reflect absorption headwinds from the rollout of higher cost inventory produced in the second half of 2025. We also expect to see a second half benefit from the recently taken actions to rightsize our cost structure. Therefore, we expect ITT performance to improve throughout the year, assuming relatively stable demand.

    此外,預計上半年的 ITT 結果將反映出 2025 年下半年生產的成本更高的庫存推出所帶來的吸收阻力。我們也預計,下半年將受惠於近期為調整成本結構所採取的措施。因此,我們預計在需求相對穩定的情況下,ITT 的業績將在全年內有所改善。

  • Within HST, new product launches are expected to contribute to stronger growth in the second half of the year compared to the first half, including Connex 360 and Dynamo. In Pharmaceuticals, we expect the previously mentioned headwinds to continue in the first half of the year. As we move into the back half of the year, we anticipate a more favorable comparison and improved performance.

    在 HST 內部,預計下半年新產品的推出將比上半年帶來更強勁的成長,其中包括 Connex 360 和 Dynamo。在製藥業,我們預計前面提到的不利因素將在今年上半年持續存在。隨著我們進入下半年,我們預期對比結果會更加有利,業績也會有所改善。

  • Finally, as a reminder, the first half of the prior year saw a benefit to operating margins related to the timing of certain functional costs being reclassified into cost of goods sold. Collectively, these factors support our expectation that organic sales growth, operating margin and adjusted earnings per share will be back half weighted.

    最後提醒一下,上年上半年營業利潤率受益於某些功能性成本重新分類為銷售成本的時間安排。綜合來看,這些因素支持了我們的預期,即有機銷售成長、營業利潤率和調整後每股盈餘將呈現後半權重成長。

  • With respect to free cash flow, similar to 2025, we expect it to be back half weighted due to our normal seasonality, expected cadence of earnings as well as recent cost structure actions.

    關於自由現金流,與 2025 年類似,我們預計其權重將佔 2025 年的一半,這是由於正常的季節性因素、預期的獲利節奏以及最近的成本結構措施所致。

  • With that, we can now open up the call for Q&A.

    接下來,我們可以開始問答環節了。

  • Operator

    Operator

  • Thank you. We will now begin the question-and-answer session

    謝謝。現在我們將開始問答環節。

  • (Operator Instructions)

    (操作說明)

  • I would like to remind participants that this call is being recorded and a digital replay will be available on the Baxter International website for 60 days at www.baxter.com.

    我想提醒各位參與者,本次電話會議正在錄音,錄音將在百特國際網站 www.baxter.com 上提供 60 天的數位回放。

  • David Roman, Goldman Sachs.

    大衛羅曼,高盛集團。

  • David Roman - Analyst

    David Roman - Analyst

  • Thank you. Good morning, everybody. I wanted to start with one strategic question and had one financial follow-up. Maybe firstly for you, Andrew, as you just think about the number of moving parts you're trying to navigate here, strategic review, catching up on innovation, deleveraging, what are you doing to ensure sustainability of the business as it relates to the competitive dynamic? And how are you gaining sufficient visibility to drive the forecasting process?

    謝謝。大家早安。我想先提出一個策略性問題,然後再跟進一個財務問題。首先,安德魯,你想想你現在要應對這麼多變化莫測的因素,策略性檢討、追趕創新步伐、降低槓桿率,為了確保企業在競爭環境中的永續發展,你做了哪些工作?您如何獲得足夠的可見性來推動預測過程?

  • Andrew Hider - Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director

    Andrew Hider - Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director

  • Yeah, . So David, look, let me start by just walking through. Part of my standard work as a CEO is to visit customers on an ongoing basis. And I'll tell you that the message is loud and clear that we are essential to not only supporting but to enabling their ability to bring high level of patient care. And we're an essential and trusted brand through that.

    是的,。大衛,你看,我先帶你走一遍。身為首席執行官,我的日常工作之一就是定期拜訪客戶。我要告訴你們,訊息非常明確,我們不僅對他們提供支持至關重要,而且對他們能夠提供高水準的患者護理至關重要。正因如此,我們成為了一個不可或缺且值得信賴的品牌。

  • As a reminder, we touch over 350 million patients per year. All that said, we need to get better. And we are not satisfied with our current performance. And you've heard me consistently talk about not only near term and to walk through, it starts with stabilizing the business. And I've outlined that in my prepared remarks.

    再次提醒大家,我們每年服務超過 3.5 億名病患。儘管如此,我們仍需改進。我們對目前的表現並不滿意。你們也聽我反覆說過,不僅要著眼於短期,而且要一步步走下去,首先要穩定業務。我在準備好的發言稿中已經闡述了這一點。

  • To get more specific, we are driving the accountability at the lowest levels in the organization. Additionally, it's about strengthening our balance sheet. And lastly, our focus on continuous improvement and really enabling that such that we focus on the customer and streamline the organization to be able to execute at the pace we expect. We're early in our journey, but we're making progress.

    更具體地說,我們正在推動組織內最基層員工承擔責任。此外,這也關乎增強我們的資產負債表。最後,我們注重持續改進,真正實現這一點,從而專注於客戶,精簡組織架構,以便能夠以我們期望的速度執行。我們才剛起步,但我們正在取得進展。

  • Now to date, we've aligned around streamlining the organization. We've launched GPS, and we've heightened our focus on innovation. And back to listening to our customers and launching products. It starts with our Connex 360 that I talked about. And then additionally, we launched earlier in the year or talked about launching earlier in the year, the Dynamo stretcher platform. So while we're making progress, we have a lot more work to do.

    目前,我們已就精簡組織架構達成共識。我們推出了GPS,並且更重視創新。回歸傾聽客戶意見和推出產品的軌道。這一切都要從我之前提到的 Connex 360 開始說起。此外,我們在今年稍早推出了(或者說,我們討論過在今年稍早推出)Dynamo擔架平台。所以雖然我們取得了一些進展,但我們還有很多工作要做。

  • Joel Grade - Executive Vice President and Chief Financial Officer

    Joel Grade - Executive Vice President and Chief Financial Officer

  • Yeah, David, and it's Joel. I'll take the forecasting piece of this thing. And clearly, improving our forecasting accuracy is a major priority. And we're attacking that in a very structured way through Baxter GPS. And look, I certainly understand and appreciate the frustration and the volatility of our historical results.

    是的,我是大衛,我是喬爾。我來負責預測部分。顯然,提高預測準確率是我們的主要任務。我們正在透過 Baxter GPS 以非常系統化的方式解決這個問題。我當然理解並體諒大家對我們歷史表現的失望與波動。

  • We're going to -- we have and will continue to be transparent about the challenges we're facing and the actions we're taking to address those challenges as well as obviously the assumptions underpinning the guidance. But GPS gives us a more disciplined operating rhythm, clear accountability and a lot more continued visibility to the drivers of our performance.

    我們將——我們已經並將繼續對我們面臨的挑戰以及我們為應對這些挑戰而採取的行動保持透明,當然,我們也會對指導方針背後的假設保持透明。但 GPS 為我們提供了更嚴謹的營運節奏、更清晰的責任劃分,以及對業績驅動因素更持續的可見性。

  • So as we -- you've heard us talk about focusing on demand planning, we also focus really around our cross-functional alignment between our commercial teams, our operational teams, our finance teams and just building a more rigorous daily, weekly operating mechanisms that really surface issues earlier and allow us to course correct more quickly.

    正如你們所聽到的,我們一直強調要專注於需求計劃,我們也真正關注的是商業團隊、營運團隊、財務團隊之間的跨職能協調,以及建立更嚴格的日常、每週營運機制,以便更早地發現問題,並使我們能夠更快地糾正方向。

  • So look, all is designed to reduce volatility, improve the predictability of our results over time. And as Andrew likes to say, drive a really consistent say-do ratio as an organization. So we know we have work to do, and we're attacking it up.

    所以你看,這一切的設計目的都是為了降低波動性,提高我們業績的可預測性。正如安德魯常說的,要作為一個組織,真正做到言行一致。所以我們知道我們還有很多工作要做,我們正在全力以赴。

  • David Roman - Analyst

    David Roman - Analyst

  • And then maybe just as a follow-up here. Can you just remind us on where you are and the progress you're making on reducing the G&A and support costs that today are getting reimbursed by Vantive via the TSA? And how we should think about the runoff of the TSA over the course of the year and into next year and your retained costs, like can that be a one-for-one offset? And maybe just help us think through the nature of the operating dynamics there.

    然後,也許可以作為後續補充。能否簡要說明一下您目前在降低一般管理費用和支援費用方面所取得的進展,這些費用目前由 Vantive 透過 TSA 報銷?我們應該如何考慮 TSA 在今年及明年期間的後續影響以及您保留的成本,例如,這是否可以實現一對一的抵銷?或許還能幫助我們釐清那裡的營運動態的本質。

  • Joel Grade - Executive Vice President and Chief Financial Officer

    Joel Grade - Executive Vice President and Chief Financial Officer

  • Yeah, sure. So a couple of things there. Number one, for 2025, one of the things we've said is that we had -- including cost takeout and TSA income, we had about a 40 basis point, I'll say, remaining impact on the year, and we are on track to that. And so I think that's been successful that way. We continue to make good progress on our cost takeout. And you've heard Andrew talk about the streamlining the operating model. That's a continued work stream on this -- we've continued to streamline our operations to meet demand. We've talked about that as well from a volume perspective.

    當然可以。所以,有兩件事需要說明。第一,對於 2025 年,我們說過的一件事是——包括成本削減和 TSA 收入在內,我們對這一年還有大約 40 個基點的影響,而且我們正朝著這個目標前進。所以我認為這種方式是成功的。我們在削減成本方面持續取得良好進展。你也聽安德魯談過簡化營運模式的事。這是我們持續進行的工作——我們一直在不斷簡化營運流程以滿足需求。我們也從銷量的角度討論過這個問題。

  • And then again, this work is done in relation to our stranded costs as well. And so our TSAs do start to tail off some in 2026. Obviously, they really go into 2027. As we've said, we are committed to eliminating our stranded costs by the end of 2027, and we remain on track to do that. So again, I feel good about that progress. And again, a lot of this work that you're hearing us talk about today is targeting that goal. So hopefully, that helps.

    此外,這項工作也與我們的擱淺成本有關。因此,我們的 TSA 數量在 2026 年開始逐漸減少。顯然,他們的計劃確實會持續到 2027 年。正如我們所說,我們致力於在 2027 年底前消除擱淺成本,我們目前仍按計劃推進這一目標。所以,我對這項進展感到滿意。再次強調,我們今天談論的許多工作都是為了實現這個目標。希望這能有所幫助。

  • David Roman - Analyst

    David Roman - Analyst

  • Yes, thank you for taking.

    是的,謝謝你抽出時間。

  • Operator

    Operator

  • Robbie Marcus, JPMorgan

    羅比馬庫斯,摩根大通

  • Robbie Marcus - Analyst

    Robbie Marcus - Analyst

  • Yeah, great, thanks for taking the questions and good morning two for me. Joel, maybe just to follow up on David's question, especially as the TSAs roll off, and I know it's early here, but do you think you'll be able to grow earnings next year as the TSAs roll off where you sit today?

    好的,謝謝您回答問題,也祝您早安。Joel,我想就David的問題做個補充,尤其是在TSA(運輸安全管理局)逐步取消的情況下,我知道現在說這些還為時過早,但你認為在你目前的處境下,隨著TSA的逐步取消,明年你的收入能夠增長嗎?

  • Joel Grade - Executive Vice President and Chief Financial Officer

    Joel Grade - Executive Vice President and Chief Financial Officer

  • Just to be really clear, next year, meaning 2027 or 2026?

    為了說清楚,明年是指 2027 年還是 2026 年?

  • Robbie Marcus - Analyst

    Robbie Marcus - Analyst

  • 2027.

    2027年。

  • Joel Grade - Executive Vice President and Chief Financial Officer

    Joel Grade - Executive Vice President and Chief Financial Officer

  • 2027. Look, we're certainly not forecasting or issuing guidance on that today. Do I anticipate growth? Yes. But I don't know that we -- as we've talked about, Robbie, the TSA typically our 24 months, our deal was closed on January 31, 2025. So the majority, I'll say, the TSAs fall off in the early part of 2027. And again, we do expect to continue to work through that for the year and again, finish that off by the end of 2027. So -- but again, we're not giving specific guidance on growth at this point.

    2027年。聽著,我們今天當然不會對此進行預測或發布指導意見。我預期會有成長嗎?是的。但我不知道我們——正如我們之前討論過的,羅比,美國運輸安全管理局通常會在我們24個月內完成交易,我們的交易於2025年1月31日完成。所以我認為,大部分TSA(運輸安全管理局)將在2027年初退出市場。我們預計今年將繼續推進這項工作,並爭取在 2027 年底前完成。所以——但是再次聲明,目前我們不會對成長給出具體指引。

  • Robbie Marcus - Analyst

    Robbie Marcus - Analyst

  • Great. Maybe a follow-up question. The gross margins obviously came in well below where the Street was and operating margin as well. I was hoping you could just bridge us from the fourth quarter '25 to the 2026 guide, how much shifted from below gross cost of goods into cost of goods? And if you could also help put a finer point on first quarter, so we could get a better sense of cadence through the year thanks.

    偉大的。或許可以問個後續問題。毛利率和營業利益率顯然都遠低於市場預期。我希望您能幫我們銜接一下 2025 年第四季到 2026 年的指導方針,有多少低於毛成本的商品轉移到了商品成本中?如果您還能幫忙更詳細地說明第一季度的情況,以便我們更了解全年的節奏,那就太感謝了。

  • Joel Grade - Executive Vice President and Chief Financial Officer

    Joel Grade - Executive Vice President and Chief Financial Officer

  • Sure. So maybe I'll start. Again, we haven't provided specific numerical guidance, but I'd certainly reiterate that I anticipate Q1 is going to be our most challenging quarter. There's a number of reasons for that, Robbie. I mean, number one, I call just our normal seasonality. Obviously, Q4 tends to be a larger -- larger quarter than Q1.

    當然。那或許我會開始。再次重申,我們尚未提供具體的數位指導,但我預計第一季將是我們最具挑戰性的一個季度。羅比,這其中有許多原因。我的意思是,第一,我稱之為正常的季節性變化。顯然,第四季往往比第一季規模更大。

  • So our margin pass-through, again, there is some typical detriment there. Now there's also a prior year comparison, remember in ITT. And while that's not a sequential driver, it does mess a little bit of the seasonality we talked about because our comparison in Q1 year-over-year with the onetime distributor build in 2025 is a little bit wonky. So at the time we sized that is about 150 basis points to total company sales. So call that a $40 million, $50 million impact, and that will be a headwind in year-to-year growth in Q1.

    因此,我們的利潤傳遞,同樣,也存在一些典型的不利因素。現在還有前一年的比較數據,記得在 ITT 也是如此。雖然這不是一個連續的驅動因素,但它確實稍微擾亂了我們討論過的季節性,因為我們第一季同比數據與 2025 年一次性分銷商建設的比較有點不准確。所以當時我們估計這大約是公司總銷售額的 150 個基點。因此,這筆損失將達到 4,000 萬至 5,000 萬美元,並將對第一季的年成長構成不利影響。

  • There's also continued uncertainty on Novum returns. One of the things we talked about in the last quarter was sort of an uncertainty around customer behavior. That uncertainty, I'd say, still exists to a degree and really carries into this year. And so our customers are a bit of a wait-and-see mode still. And therefore, as we referenced last quarter, there's an ongoing risk for customer responses there. With that -- again, this is all top line, but Drug Compounding in Q4, 18% growth, probably not necessarily sustainable from that number. And so obviously, expecting that to be lower in Q1.

    Novum的收益也持續存在不確定性。我們在上個季度討論過的問題之一是客戶行為的不確定性。我認為,這種不確定性在某種程度上仍然存在,而且確實延續到了今年。因此,我們的客戶目前仍持觀望態度。因此,正如我們上個季度提到的那樣,客戶回饋方面仍然存在風險。綜上所述—以上皆為整體數據,但第四季藥物配製業務成長了 18%,這個數字可能並不可持續。因此,很顯然,預計第一季會更低。

  • And then from a margin perspective, again, I already referenced some of the lower volume. There's also what I'll call absorption headwinds. So again, in 2025, we had some of these higher manufacturing costs and that ended up in our inventory capitalization.

    從利潤率的角度來看,我之前已經提到了一些成交量較低的情況。此外,還有一些我稱之為吸收方面的不利因素。所以,到了 2025 年,我們又面臨了一些較高的製造成本,最終這些成本都反映在我們的庫存資本化中。

  • That is then rolling out as we sell those products, obviously, in the first half of the year really, but also certainly in Q1. And so that's an incremental headwind. The margins did not -- we haven't given specific guidance around the number on that.

    然後,隨著我們銷售這些產品,這項措施就會逐步推出,顯然,主要是在今年上半年,但肯定也會在第一季推出。所以,這算是逐漸增加的不利因素。利潤率沒有變化——我們還沒有就此給出具體數字的指導。

  • And then the other thing is we continue to expect pharma margins to remain pressured due to softness in Injectables & Anesthesia and then really just the overall mix of the business. So I guess, finally, what I'd say from an EPS perspective, Robbie, the interest -- incremental interest expense kicks in, in Q1. And so that's certainly something to expect there. So that's -- so again, hopefully, that helps with some of the guidance there.

    此外,我們預計由於注射劑和麻醉劑業務疲軟以及整體業務結構的變化,製藥業的利潤率將繼續承壓。所以,最後我想說的是,從每股盈餘的角度來看,羅比,利息-新增利息支出將在第一季開始產生。所以,這種情況在那裡肯定會發生。所以,希望這些指導能有所幫助。

  • Robbie Marcus - Analyst

    Robbie Marcus - Analyst

  • Very much, thanks a lot.

    非常感謝。

  • Operator

    Operator

  • Vijay Kumar, Evercore ISI

    Vijay Kumar,Evercore ISI

  • Vijay Kumar - Equity Analyst

    Vijay Kumar - Equity Analyst

  • Hey guys, thank you for taking my question. Andrew, maybe my first one for you is you mentioned customers are awaiting how you resolve Novum, right? But your guidance assumes Novum ship hold remains in place for the full year. Have you communicated this to customers? Like what have you told customers, right? I understand the guidance assumption, but I'm curious, are customers willing to wait for a year for Novum to resolve?

    各位好,感謝你們回答我的問題。Andrew,我首先要問你的是,你提到客戶都在等你如何解決 Novum 的問題,對嗎?但您的指導意見假設 Novum 船舶的停駛將持續一整年。您是否已將此訊息傳達給客戶?就像你跟顧客說的那樣,對吧?我理解指導意見中的假設,但我很好奇,客戶是否願意等待一年時間讓 Novum 解決問題?

  • Andrew Hider - Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director

    Andrew Hider - Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director

  • Yeah, good morning, Vijay. So let me walk this through a little bit here. So first and foremost, customers can and are continuing to use the device according to existing instructions and mitigating actions. We've continued to make progress on our Novum solution and the corrections, and we're staying close. And as we go through testing, as we go through really identifying the longer-term solution set, we will update.

    早安,維傑。讓我來簡單解釋一下。因此,首先,客戶可以而且正在繼續按照現有的說明和緩解措施使用該設備。我們在 Novum 解決方案和修正方面持續取得進展,並且我們密切關注著進展。隨著我們進行測試,隨著我們真正確定長期解決方案,我們將進行更新。

  • As a reminder, we have a strong pump portfolio. We have our Spectrum LVP that we utilize through this transition. And I even walked through earlier in the year, we've launched Spectrum with the IQX platform. And it enables us to really not only work with our customers, but to have a total pump portfolio with Spectrum being our LVP and Novum being our syringe and Novum being a newer product set that we've launched in the recent history.

    再次提醒大家,我們擁有強大的幫浦產品組合。我們在過渡期間將使用我們的 Spectrum LVP。我甚至在今年早些時候就詳細介紹過,我們已經推出了基於 IQX 平台的 Spectrum。這使我們能夠真正與客戶合作,並擁有完整的泵浦產品組合,其中 Spectrum 是我們的 LVP,Novum 是我們的注射器,Novum 是我們最近推出的新產品系列。

  • And so while we're going through our Novum updates, we have a strong platform that we can bring to market. And as a reminder, we're also launching early Q2 Pure-Vu on the IQX platform. And Pure-Vu is designed to really support our customers and their ability to identify and work on fluid processing. So we're continuing to innovate, continuing to build on. And given our pump platform, we are in a position to support our customers through this.

    因此,在我們進行 Novum 更新的同時,我們擁有一個強大的平台,可以將其推向市場。另外提醒一下,我們將在第二季初在 IQX 平台上推出 Pure-Vu。Pure-Vu 的設計旨在真正支持我們的客戶及其識別和處理流體處理的能力。所以我們會繼續創新,繼續發展。憑藉我們的泵平台,我們有能力在過程中為客戶提供支援。

  • Vijay Kumar - Equity Analyst

    Vijay Kumar - Equity Analyst

  • Understood. And maybe my second one for you, Andrew. You mentioned the operating model change. Curious on what has changed from prior model, right? How is this model better? And what's the impact or implication of free cash flow? I know you mentioned P&L responsibility. Is free cash flow going to improve from fiscal '25?

    明白了。或許這是我為你準備的第二首歌,安德魯。您提到了營運模式的改變。是不是很好奇新模型和之前的模型相比有哪些變化?這個模型有哪些優點?自由現金流的影響或意義是什麼?我知道你提到了損益責任。2025財年起,自由現金流會改善嗎?

  • Andrew Hider - Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director

    Andrew Hider - Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director

  • Yeah, So I guess I'll take the first part, and then I'll let Joel walk through a little bit around the cash process. Look, just a few weeks ago, we internally announced the new operating model, and it's designed around simplifying our organization, accelerating innovation and improving performance. And we are putting the accountability at the lower levels in the organization. And I would say most significantly or one of the areas is delayering at the top level, removing the segment management and embedding critical functional roles directly into the business.

    好的,那我先講第一部分,然後讓喬爾簡單介紹一下現金處理流程。你看,就在幾週前,我們內部宣布了新的營運模式,其設計宗旨是簡化我們的組織,加速創新,提高績效。我們將問責制下放到組織中較低層級。我認為最重要的方面之一是高階扁平化管理,取消部門管理,並將關鍵職能角色直接嵌入業務中。

  • And so this allows us to really further eliminate the barriers for decision-making. And it's streamlining to listening to our customers and ultimately helping us improve our say-do ratio and execute on a more consistent basis. So this approach is really moving down that decentralizing and streamlining the organization with black dot accountability.

    因此,這使我們能夠真正進一步消除決策障礙。這有助於我們更有效地傾聽客戶的意見,並最終幫助我們提高言行比,並更穩定地執行任務。所以這種方法其實是在逐步下放權力,簡化組織,並實行黑點問責制。

  • Joel Grade - Executive Vice President and Chief Financial Officer

    Joel Grade - Executive Vice President and Chief Financial Officer

  • Yeah, Vijay. And then I'll take in the cash piece of this. Certainly, as you've heard Andrew talk about regularly and myself as well as improving our balance sheet cash generation continues to be a top priority for the company. We do expect in '26 that free cash flow will improve versus 2025, driven primarily by stronger working capital performance and as well, obviously, what we don't expect to repeat some of the onetime hits that happened in 2025, specifically the expenses for the hurricane.

    是的,維傑。然後我會收取這筆款項中的現金部分。當然,正如你經常聽到安德魯和我談到的那樣,改善資產負債表、提高現金流仍然是公司的首要任務。我們預計 2026 年的自由現金流將比 2025 年有所改善,這主要得益於營運資本表現的增強,而且顯然,我們預計不會重蹈 2025 年某些一次性打擊的覆轍,特別是颶風造成的損失。

  • From a free cash flow perspective, we do also -- similar to 2025, we do expect it to be somewhat back half related. That is -- that includes a charge in Q1 related to recent operating model and cost structure actions as well as some of the seasonality that we typically show.

    從自由現金流的角度來看,我們也認為——與 2025 年類似,我們預計它在某種程度上與下半年有關。也就是說,這包括第一季與近期營運模式和成本結構調整相關的費用,以及我們通常體現的一些季節性因素。

  • But we also do expect, as we've talked about from a P&L standpoint, our earnings tend to be skewed towards the second half of the year due to some of the structural impacts that have been recognized and we expect to recognize in H2, again, as well as some of the impact from the manufacturing side of our business in terms of adjusting to better volumes.

    但正如我們從損益表角度所討論的那樣,我們也預計,由於一些已經確認和我們預計在下半年將再次確認的結構性影響,以及我們業務製造方面為適應更好的產量而做出的一些調整,我們的收益往往會偏向下半年。

  • I'm confident in that. Why? Again, some of the impacts are driven by actions that are in flight. So again, the structural cost work in flight, the work around adjusting our manufacturing operations for better impact on volumes in flight. And so I think -- and then the biggest, again, year-over-year drivers I mentioned really around working capital, inventory management, improved receivable collection processes and tighter control over payables process, including, I'll say, commercial terms.

    我對此很有信心。為什麼?再次強調,有些影響是由正在進行中的行動造成的。所以,再次強調,結構性成本控制工作正在進行中,我們需要調整生產運營,以更好地提高產量。所以我認為——再次強調,我提到的最大的同比驅動因素實際上是圍繞營運資本、庫存管理、改進的應收帳款催收流程以及對應付帳款流程的更嚴格控制,包括商業條款。

  • So -- but GPS is playing a role in this as well, giving us a more consistent operating cadence better visibility to reduce volatility and that overall strength in our cash conversion. So again, we do expect cash flow to continue to move in the right direction as we execute through 2026. Again, we saw some of that already in the fourth quarter of 2025.

    所以——但 GPS 也發揮了作用,它為我們提供了更穩定的營運節奏、更好的可視性,從而降低了波動性,並增強了我們的現金轉換能力。因此,我們再次預計,隨著我們執行到 2026 年,現金流將繼續朝著正確的方向發展。同樣,我們在 2025 年第四季已經看到了一些這樣的跡象。

  • Operator

    Operator

  • Larry Biegelsen, Wells Fargo.

    拉里·比格爾森,富國銀行。

  • Larry Biegelsen - Analyst

    Larry Biegelsen - Analyst

  • Good morning. Thanks for taking the question. Two for me, one on the gross margin, one on pharma. Joel, could you please give us a little bit more color on the Q4 gross margin? How much of the year-over-year decline was due to tariff mix, reclassifications and the onetime items you called out? And how much lower do you expect the gross margin to be in '26 versus '25? I assume it's more than the decline we see in the operating margin guidance. And I had one follow-up.

    早安.感謝您回答這個問題。對我來說有兩個方面,一個是毛利率,一個是醫藥行業。喬爾,能否請你詳細介紹一下第四季的毛利率狀況?同比下降中有多少是由於關稅結構、重新分類以及您提到的一次性項目造成的?您預計 2026 年的毛利率會比 2025 年下降多少?我估計這比我們在營業利潤率預期中看到的下降幅度還要大。我還有一個後續問題。

  • Joel Grade - Executive Vice President and Chief Financial Officer

    Joel Grade - Executive Vice President and Chief Financial Officer

  • Yeah, thanks, Larry. I appreciate the question. So from -- again, I'll call gross margin and again, our overall operating margin standpoint, certainly, a few factors played into this. I mean we had an unfavorable mix of sales. So again, with business mix, I'll say, geographic mix, product mix, that certainly was a key element to this. We also had, as was referred to earlier, some higher manufacturing and supply costs really for a couple of different reasons.

    是啊,謝謝你,拉里。感謝您的提問。所以,從毛利率,也就是我們整體的營業利益率來看,當然,有幾個因素影響了這一點。我的意思是,我們的銷售組合不太理想。所以,再說一遍,就業務組合而言,例如地理組合、產品組合,這無疑是關鍵因素。如同前面所提到的,由於一些不同的原因,我們的製造成本和供應成本也較高。

  • One, obviously, some of the challenges we had aligning, again, our labor to volumes, but also some of the impacts that Andrew mentioned related to some of the challenges that we've seen in pharma. Those factored into this as well.

    顯然,我們面臨的一些挑戰之一是使勞動力與產量相匹配,但安德魯提到的一些影響也與我們在製藥領域看到的一些挑戰有關。這些因素也影響了最終結果。

  • The nonrecurring items, again, I would classify that as it around $40 million of impact that were related to gross and operating margins in the quarter. So certainly, those are things to contemplate as part of that. So I would say that's really the main drivers there. Again, as I indicated, about $40 million of that nonrecurring.

    對於非經常性項目,我再次將其歸類為與本季毛利率和營業利潤率相關的約 4,000 萬美元的影響。所以,這些都是需要考慮的因素。所以我認為這才是真正的主要驅動因素。正如我之前提到的,其中約有 4000 萬美元是非經常性支出。

  • Larry Biegelsen - Analyst

    Larry Biegelsen - Analyst

  • And Joel, 2026 versus '25 gross margin, I didn't hear that.

    喬爾,2026 年與 2025 年的毛利率對比,我沒聽過。

  • Joel Grade - Executive Vice President and Chief Financial Officer

    Joel Grade - Executive Vice President and Chief Financial Officer

  • Yeah, I again, we haven't given specific guidance on that. I guess what I would say a little bit to the commentary that I had as it relates to sort of the Q4 to Q1. I'd say there's some of these impacts that we expect to continue into 2026.

    是的,我們還沒有就此給出具體指示。我想就我之前對第四季到第一季情況的評論稍作補充。我認為其中一些影響預計會持續到 2026 年。

  • And I think about a little bit of this as H1, H2 kind of part of the year. In other words, this is going to continue to improve over the second half of the year, but there's really two factors, I'd say, in H1 that I would consider as part of the -- one is I'll call mathematical and then one is more just kind of actions that are driving outcomes.

    我認為這有點像是上半年、下半年的某個階段。換句話說,這種情況將在下半年繼續改善,但我認為,上半年有兩個因素會被視為其中的一部分——一個是數學因素,另一個則是推動結果的行動因素。

  • So the mathematical piece, again, we do have some normal seasonality in our company between H1 and H2 from a pure volume perspective. That certainly we'd expect to continue. And then our cadence reflects a more challenging first half with the improvement in the second half. ITT absorption headwinds, again, this is something that in the first half, we had higher cost of inventory that we capitalized.

    所以從數學角度來看,從純粹的交易量角度來看,我們公司上半年和下半年之間確實存在一些正常的季節性波動。我們當然希望這種情況能夠持續下去。然後,我們的節奏反映了上半場更具挑戰性,而下半場則有所改善。ITT 吸收方面的不利因素再次出現,這是上半年我們庫存成本較高,但我們已經將其資本化的問題。

  • And that obviously, we saw benefits there that's going to then roll into the first half of this year. So that's essentially a headwind in the first half of 2026. So those are the mathematical pieces as well as tariffs. Remember, we didn't have tariffs in the first half of last year.

    很顯然,我們看到了其中的好處,這些好處將延續到今年上半年。所以,這基本上意味著2026年上半年將面臨不利因素。所以,這些就是相關的數學知識以及關稅問題。請記住,去年上半年我們沒有徵收關稅。

  • Then as it relates to the actions driving outcomes, there's a couple of elements to this. One is the structural cost takeout that we've talked about. The impact of that is, obviously, again, those actions are in place. Again, confident in the work that we're doing, but the outcomes of that are primarily going to be impacted in the second half of the year.

    那麼,就影響結果的行動而言,這其中包含兩個要素。一是我們已經討論過的結構性成本削減。顯然,其影響在於,這些措施已經到位。再次重申,我對我們正在做的工作充滿信心,但這些工作的成果主要會在今年下半年受到影響。

  • And then in terms of aligning our manufacturing labor with our volumes and our production costs, again, that impact will start to show itself in the second half of the year because again, we're still, I would say, taking the hit, if you will, from the capital mill as we sell those products in the first half of the year.

    至於使我們的製造業勞動力與產量和生產成本相匹配,這種影響將在下半年開始顯現,因為可以說,我們在上半年銷售這些產品時,仍然會受到資本投入的衝擊。

  • Larry Biegelsen - Analyst

    Larry Biegelsen - Analyst

  • That's helpful. And Andrew, thanks for giving us the P&Ls by segment. Pharma has an operating margin of 9% was even lower in Q4. My guess is compounding, which is your fastest-growing business, doesn't make a lot of money. What are you doing to improve the margins in this business? And why does it make sense to keep a low-margin business like compounding that seems to hurt your kind of mix every quarter?

    那很有幫助。安德魯,謝謝你給我們提供了各業務板塊的損益表。製藥業的營業利潤率為 9%,第四季甚至更低。我猜想,複利成長(也就是你成長最快的事業)並不會賺很多錢。為了提高這家企業的利潤率,你們採取了哪些措施?為什麼保留像複利這樣利潤率低、似乎每季都會傷害你投資組合的公司?

  • Andrew Hider - Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director

    Andrew Hider - Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director

  • Yeah, and I'll just -- I'll walk through kind of the fundamentals of pharma and really outline. So overall, we like the fundamentals of this business. And just a couple of items. We've also taken this part of the organization, and we've combined it with our ITT business. And the reason being is it's synergistic with that organization, and it's common customers, common call points, and there's an opportunity to improve the business. And we have and we're continuing to take actions to do so.

    是的,我會——我會簡單介紹一下製藥業的基本原理,並進行概述。總的來說,我們看好這家公司的基本面。還有幾樣東西。我們也接手了這部分組織,並將其與我們的 ITT 業務合併了。原因在於它與該組織具有協同效應,擁有共同的客戶、共同的聯繫點,並且有機會改善業務。我們已經並將繼續採取行動來實現這一目標。

  • Additionally, there's been some areas that have been in our control that we've been challenged with. And through GPS and through this identification with driving the accountability at the lowest levels, we've taken critical actions around aligning to improve.

    此外,我們在一些原本可以掌控的領域也遇到了挑戰。透過 GPS 以及這種在最基層推動問責制的識別,我們採取了關鍵行動來協調改進。

  • And one of them is around operational execution. And not to get into too much specifics, but we saw one of our facilities really hindered by the ability to drive output. And we took an action team around this. They've already improved. They're continuing to improve. We're going to see that performance through the -- improve through the first half of the year.

    其中之一就是營運執行。我不想透露太多細節,但我們發現我們的一家工廠由於產能不足而受到了嚴重阻礙。我們為此成立了一個行動小組。他們已經有所進步。他們正在不斷進步。我們將看到這種表現——在今年上半年有所改善。

  • But more importantly, it's around how do we not get back into the situation. How do we build this and have this being sustained performance. And the role GPS plays in that is around identification and critical action. The second piece within our control is we had a supplier challenge.

    但更重要的是,我們該如何避免重蹈覆轍。我們如何才能建立這樣的系統並使其保持持續的效能?GPS 在其中發揮的作用是識別和採取關鍵行動。第二件我們可以控制的事情是,我們遇到了供應商的問題。

  • And to be quite candid, it was an area that we identified, we are working through. It is going to take us a part of the year to get through this, and we're identifying how we have alternatives to continue to support the product. We are continuing to shift. That said, we are looking to identify for long-term solutions.

    坦白說,這是我們發現並正在努力解決的領域。我們需要花一年中的部分時間來解決這個問題,我們正在研究如何尋找替代方案來繼續支援該產品。我們正在持續轉型。也就是說,我們正在尋找長期的解決方案。

  • So to answer your question, head on, we like the fundamentals of the business. We've got some work to do here, and we need to continue to align around the value creation we have for our customers.

    所以,直接回答你的問題,我們喜歡這家企業的基本面。我們還有一些工作要做,我們需要繼續圍繞我們為客戶創造的價值進行調整。

  • Joel Grade - Executive Vice President and Chief Financial Officer

    Joel Grade - Executive Vice President and Chief Financial Officer

  • And Larry, two other things I would maybe just add to that. I think number one is in the -- some of the margin challenges that we saw in Q4, certainly, as Andrew said, that starts to improve over the second part of the year, but we still anticipate that being an impact in Q1.

    拉里,我可能還要補充兩點。我認為第一點是——我們在第四季度看到的一些利潤率挑戰,當然,正如安德魯所說,這種情況會在今年下半年開始好轉,但我們仍然預計這會對第一季產生影響。

  • And then the second piece of this, just the one reminder as it relates to the compounding business. I mean, yes, certainly, that mix impact is a margin impact as well in terms of the relative level of growth in compounding to our Injectables & Anesthesia. The one thing about that business, it is our fastest cash cycle in the business. So that is one area that just as a reminder, that is a benefit from that particular business.

    第二點,也是關於複利業務的一點提醒。我的意思是,是的,當然,這種組合變化也會對利潤率產生影響,因為它會影響我們注射劑和麻醉劑業務的複合成長相對水平。這家公司最大的特色就是它的現金週轉速度是我們公司所有公司中最快的。所以,需要提醒的是,這是該特定企業帶來的一個好處。

  • Operator

    Operator

  • Travis Steed, Bank of America

    特拉維斯·斯蒂德,美國銀行

  • Travis Steed - Analyst

    Travis Steed - Analyst

  • Hey Joel, just still trying to -- a little confused on what to put in the model for Q1 and to understand kind of the slope of the recovery in '26. And is revenue kind of down low single digits, down mid-single digits? Are gross margins, op margins flat, down sequentially? What percent of earnings should fall in Q1 versus kind of the second half of the year? Just any more details on how to model the Q1?

    嘿,喬爾,我還在嘗試——有點困惑第一季的模型應該包含什麼,以及理解2026年復甦的斜率。營收是否出現了個位數低幅或個位數中幅的下滑?毛利率和營業利潤率是持平還是月減?第一季財報應該比下半年下降多少百分比?關於如何對Q1進行建模,還有更多細節嗎?

  • Joel Grade - Executive Vice President and Chief Financial Officer

    Joel Grade - Executive Vice President and Chief Financial Officer

  • Yeah, thanks for the question. So again, we haven't specifically given numerical guidance on the quarters. Again, the thing I would just continue to reiterate is the fact that, again, there's a number of these key elements that are impacting Q1. Again, even I'd say, as we even contemplated that relative to Q4. Again, I'll just run through a couple of them again.

    謝謝你的提問。所以,我們再次重申,我們沒有具體給出季度數位指引。我再次重申,有很多關鍵因素正在影響第一季。再說一遍,即使是我也會說,我們甚至考慮過與第四季相關的問題。我再重複一遍其中幾個例子。

  • And the -- again, there's a volume and seasonality impact that occurs. There's the continued elements of uncertainty around our Novum customer behavior around our Novum LVP returns. Again, there's likely, as I just referenced on the last, continued challenges from a pharma perspective as it relates to our overall margin.

    而且——同樣,交易量和季節性因素也會對其產生影響。關於 Novum LVP 退貨,我們的 Novum 客戶行為仍有許多不確定因素。正如我剛才提到的,從製藥業的角度來看,我們的整體利潤率可能還會面臨持續的挑戰。

  • And again, the headwinds from an absorption standpoint, again, we capitalized into our inventory costs, some of the higher costs that we experienced in 2025. As we head into 2026, and we -- again, those are going into our COGS. And so as we sell those products, those are essentially selling higher-priced inventory as we head into the first quarter and H2 in general.

    此外,從吸收的角度來看,我們也遇到了一些不利因素,這些因素都計入了我們的庫存成本中,我們在 2025 年經歷了一些較高的成本。隨著我們邁入 2026 年,我們——再次強調,這些都將計入我們的銷售成本。因此,隨著我們進入第一季和下半年,這些產品本質上是在銷售價格更高的庫存。

  • So those are some of the main issues that are driving that and again, on an EPS level, interest expense kicking in. I think that's -- those are really the main key drivers I would think about as to why our first half and specifically first quarter remains particularly challenging.

    所以這些是導致這種情況的一些主要因素,而且,從每股盈餘 (EPS) 的角度來看,利息支出也開始增加。我認為,這些確實是導致我們上半年,特別是第一季仍然充滿挑戰的主要原因。

  • Travis Steed - Analyst

    Travis Steed - Analyst

  • Okay. We'll hopefully get more offline. Two little kind of nitpicky questions. One, just kind of curious if you're assuming share gains or share losses in infusion pumps this year. And OUS Care & Connectivity Solutions was up $50 million sequentially. Was there anything kind of onetime in that line item?

    好的。希望以後能有更多人離線。兩個有點吹毛求疵的小問題。一,我只是有點好奇,您認為今年輸液幫浦的市佔率會上升還是下降?OUS Care & Connectivity Solutions 的營收季增了 5,000 萬美元。該項內容中是否有一次性支出?

  • Andrew Hider - Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director

    Andrew Hider - Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director

  • Yeah, So I guess I'll start with the first question here. Look, we have good opportunities as we go into the year. And as a reminder, Spectrum is a workhorse in the space. And not only is the workhorse, we continue to innovate on the platform. And now that it speaks with Novum syringe, we're continuing to be confident in our ability to bring high value to the market we serve.

    好的,那我就先回答第一個問題吧。你看,今年我們有很多好機會。再次提醒大家,Spectrum 是該領域的佼佼者。而且它不僅是主力平台,我們還在該平台上不斷進行創新。現在它與 Novum 注射器相容,我們對能夠為我們服務的市場帶來高價值的能力充滿信心。

  • Joel Grade - Executive Vice President and Chief Financial Officer

    Joel Grade - Executive Vice President and Chief Financial Officer

  • Can you repeat the second part of your question, I'm sorry?

    不好意思,你能再說一次你問題的第二部分嗎?

  • Travis Steed - Analyst

    Travis Steed - Analyst

  • Yeah, International Care & Connectivity Solutions was up $50 million sequentially. I didn't know if there was anything onetime in there. It looked like a big growth rate in the international business.

    是的,國際關懷與互聯解決方案業務環比成長了5000萬美元。我不知道裡面有沒有曾經有過什麼。國際業務看起來成長勢頭強勁。

  • Joel Grade - Executive Vice President and Chief Financial Officer

    Joel Grade - Executive Vice President and Chief Financial Officer

  • Yeah, International Care & Connectivity Solutions was up $50 million sequentially. I didn't know if there was anything onetime in there. It looked like a big growth rate in the international business.

    是的,國際關懷與互聯解決方案業務環比成長了5000萬美元。我不知道裡面有沒有曾經有過什麼。國際業務看起來成長勢頭強勁。

  • I mean I would just say, in general, that business has been performing well. I don't know that there's anything onetime. I would say, in general, in the overall CPS business, again, we've got a strong order book. We've talked about that.

    我的意思是,總的來說,這家公司業績表現良好。我不知道有沒有一次性的事情發生。總的來說,就整個 CPS 業務而言,我們的訂單量仍然強勁。我們討論過這個問題。

  • We've had some competitive wins from a customer standpoint, again, capital spend in general remains really kind of strong across our geographies. So I don't know if there's anything unusual or onetime there, just that, that business has a continued strong business, and they've continued to improve outside the US, which was somewhat of a headwind last year.

    從客戶的角度來看,我們取得了一些競爭優勢;此外,我們各個地區的資本支出總體上仍然非常強勁。所以我不知道那裡是否有任何不尋常或一次性的情況,只是這家公司一直保持著強勁的業務,並且在美國以外的地區也持續改善,而去年在美國以外地區,這在某種程度上是一個不利因素。

  • Travis Steed - Analyst

    Travis Steed - Analyst

  • Okay, thank you.

    好的,謝謝。

  • Operator

    Operator

  • Danielle Antalffy, UBS

    瑞銀集團 Danielle Antalffy

  • Danielle Antalffy - Equity Analyst

    Danielle Antalffy - Equity Analyst

  • Hey, good morning, guys. Thank you so much for taking the question. Andrew, I appreciate it's not been terribly long. But I guess I'm just curious about looking at the Baxter portfolio in its totality, sort of how you feel about the state of the portfolio today, appreciating you're not going to be doing probably M&A anytime soon.

    嘿,各位早安。非常感謝您回答這個問題。安德魯,我知道時間不算太長。但我很好奇,從整體來看,您對百特集團的投資組合有何看法,也知道您近期可能不會進行併購。

  • But a, sort of where you see the most exciting opportunities with the current portfolio that might be underappreciated by investors? And then b, where you think there's opportunity to sort of ramp up the product portfolio? Thanks so much.

    但是,您認為目前投資組合中最令人興奮的機會在哪裡,而這些機會可能被投資者低估了呢?那麼,b,您認為在哪些方面有機會擴大產品組合?非常感謝。

  • Andrew Hider - Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director

    Andrew Hider - Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director

  • You bet. And if I missed something, Danielle, certainly feel free to jump in. I'll take this as you outlined in the question. So look, Baxter is fundamental, and it's fundamental to the health care system. And as I mentioned earlier in the call, it's a trusted partner. We have market leadership across multiple product categories. We have a resilient portfolio and deep customer relationships that really give us a competitive advantage.

    當然。如果我漏掉了什麼,丹妮爾,你當然可以隨時補充。我會按照你在問題中描述的方式來回答。所以你看,百特公司至關重要,它對醫療保健系統至關重要。正如我之前在電話會議中提到的,它是一家值得信賴的合作夥伴。我們在多個產品類別中都處於市場領先地位。我們擁有穩健的產品組合和深厚的客戶關係,這真正賦予了我們競爭優勢。

  • Now as we go forward, innovation will be a critical element to our success. And as we look at innovation as an enabler, it's really extremely important as we bring new innovation to the market and not only from listening to our customers and identifying the pain points to solution, but also just that staying in front of our total portfolio of product set.

    展望未來,創新將是我們成功的關鍵因素。當我們把創新視為一種推動力時,它就顯得尤為重要,因為我們需要將新的創新推向市場,這不僅體現在傾聽客戶的意見並找出解決方案的痛點,還體現在我們始終關注我們的全部產品組合。

  • So there's an opportunity to not only improve our performance, but GPS becomes the foundational and foundation for how we really drive disciplined not only operating rhythm, but also clear accountability and clear enablement to listen to our customers, streamline our ability to bring strong capability to the market and really have real-time visibility to bring innovation to solve issues and to solve challenges that our customers face.

    因此,我們不僅有機會提高績效,而且 GPS 還成為我們真正推動嚴謹的營運節奏、明確的問責制和明確的賦能的基礎,從而傾聽客戶的意見,簡化我們向市場推出強大能力的能力,並真正擁有實時可見性,從而帶來創新來解決客戶面臨的問題和挑戰。

  • So I like the fundamentals of where we sit, certainly areas we need to continue to challenge on and there are some areas internationally that we're looking at. We do have smaller exits that we're looking at in '26 as we look at our total portfolio.

    所以我對我們目前的基本狀況很滿意,當然也有一些領域我們需要繼續努力,還有一些國際領域是我們正在關注的。鑑於我們對整體投資組合的審視,我們確實在考慮 2026 年的一些較小的退出項目。

  • And as far as areas where I just -- I called it out in the call, we're pleased with our performance in many of our businesses, but more specifically, in how we bring our solution from not only our Advanced Surgery business, but the capability we have in that space and how customers look to Baxter to support and have high value when they're treating and working with patients.

    至於我在電話會議中提到的領域,我們對我們在許多業務方面的表現感到滿意,更具體地說,我們對我們如何提供解決方案感到滿意,這不僅體現在我們的高級外科手術業務中,還體現在我們在該領域的能力,以及客戶如何期望百特在治療和與患者合作時提供支持並獲得高價值。

  • But we have many of those. MPT has areas we're looking at as well as HST and as well as pharma. So more to come. And if I could just characterize how we think about innovation for the future, it's a base hit discussion, not walk off grand slam. It's about that constant drive to launch products, to launch solutions that really enable our customers to bring higher level of care at a more efficient pace.

    但我們有很多這樣的情況。MPT、HST 以及製藥領域都是我們正在關注的領域。敬請期待更多內容。如果讓我概括一下我們對未來創新的看法,那就是:這是一場循序漸進的討論,而不是一場驚天動地的全壘打。關鍵在於不斷推出產品、推出解決方案,真正幫助我們的客戶以更有效率的方式提供更高水準的照護。

  • And lastly, on capital allocation, it is a critical element. We talk as direct on capital allocation as we do around our market strategy. And I've outlined, it starts with delevering our balance sheet, and we've taken critical actions around that.

    最後,在資本配置方面,這是一個關鍵因素。我們在資本配置問題上的討論,與我們在市場策略上的討論一樣直接。我已經概述過了,首先要降低資產負債率,我們已經圍繞這一點採取了關鍵措施。

  • When we look at the other levers, reinvesting in the business, and I walked through, we're going to be at or above on our innovation reinvestment, expecting new product launches, expecting areas to drive R&D, not just sustainment, but also as we get into future and we delever, identifying targets that can add high value from an M&A perspective. And we have a strong funnel, but we need to delever first. So hopefully, I answered your question.

    當我們審視其他槓桿,例如對業務的再投資時,正如我之前提到的,我們將在創新再投資方面達到或超過預期,期待新產品的推出,期待推動研發的領域,不僅僅是維持現狀,而且隨著我們進入未來並降低槓桿率,還要從併購的角度確定能夠增加高價值的目標。我們擁有強大的銷售漏斗,但首先需要降低槓桿率。希望我的回答能幫助你。

  • Danielle Antalffy - Equity Analyst

    Danielle Antalffy - Equity Analyst

  • Yeah, no, very helpful. Thanks, Andrew.

    是的,確實很有幫助。謝謝你,安德魯。

  • Andrew Hider - Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director

    Andrew Hider - Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director

  • Appreciate it.

    謝謝。

  • Operator

    Operator

  • Joanne Wuensch, Citi.

    Joanne Wuensch,花旗銀行。

  • Joanne Wuensch - Analyst

    Joanne Wuensch - Analyst

  • Good morning and thank you for squeezing me in. I'm just curious, when you went to put guidance together for 2026, what was sort of your philosophy of how to deliver it so you can deliver on the guidance? Thank you.

    早安,謝謝你們擠出時間陪我。我只是好奇,當您制定 2026 年的指導方針時,您的理念是什麼,才能確保這些指導方針得以實現?謝謝。

  • Joel Grade - Executive Vice President and Chief Financial Officer

    Joel Grade - Executive Vice President and Chief Financial Officer

  • Thanks, Joanne. I'll take a stab at that and if Andrew wants to add anything he can. Look, I always view guidance. I think I collectively view guidance as prudent and reflective of the best and most current information we have available.

    謝謝你,喬安妮。我先試著回答一下,如果安德魯想補充什麼,他也可以。你看,我總是會參考指導意見。我認為,總體而言,這些指導意見是審慎的,反映了我們目前所掌握的最佳和最新資訊。

  • And so we think about these things as trying to continue to be very transparent about the challenges we're facing. This is certainly apparent in our Q4 results, but also about the actions we're taking to address those issues. We try to talk about some of the things that are market conditions, but also things that are in our control to deal with.

    因此,我們認為應該繼續保持高度透明,坦誠地面對我們所面臨的挑戰。這一點在我們的第四季業績中顯而易見,同時也體現在我們為解決這些問題所採取的行動中。我們試著討論一些市場狀況的問題,以及一些我們可以控制和應對的問題。

  • And so -- and obviously, all that kind of falls in the underlying assumptions underpinning the guidance. And so as we sort of put all that together and then think about some of the key factors in the year that are happening, again, we certainly -- we talked about the fact that there's a key Novum assumption that was in there.

    因此——顯然,所有這些都屬於指導方針所依據的基本假設。因此,當我們把所有這些因素綜合起來,並思考今年發生的一些關鍵因素時,我們當然也談到了 Novum 的一個關鍵假設。

  • We've talked about our IV Solutions that we rebased that. We've talked about some of the challenges in our injectables and our anesthesia, some of the product mix impacts, again, the manufacturing volumes that we had to adjust to and some of the -- what we say in the 2026 is going to be a reduced contribution from pricing as well as the EPS impact.

    我們已經討論過我們重新制定的靜脈輸液方案。我們已經討論過注射劑和麻醉劑方面的一些挑戰,一些產品組合的影響,以及我們不得不調整的生產量,還有一些——我們預計到 2026 年,價格貢獻以及每股收益的影響將會減少。

  • So Joanne, I guess I'd say when we pull that all together, that's where our guidance shakes out. Certainly, again, I said earlier in the call, I certainly understand the frustration and some of our volatility in the way we hit this again, it matters to us a ton for our say-do ratio to be in a place where we actually -- again, here's what we say and then here's what we do in terms of that relative to our guidance. But hopefully, that -- I don't know, Andrew, is there anything you'd add to that?

    所以喬安妮,我想說的是,當我們把所有這些因素綜合起來考慮時,這就是我們指導方針的最終體現。當然,正如我之前在電話會議中所說,我當然理解大家的沮喪,也理解我們在應對這種情況時出現的一些波動。對我們來說,言行一致至關重要,這樣我們才能真正做到言行一致,並與我們的指導方針保持一致。但希望如此——我不知道,安德魯,你還有什麼要補充的嗎?

  • Andrew Hider - Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director

    Andrew Hider - Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director

  • And I would just say -- I'll echo. It's a view of the market. It's our prudent view of how we will operate. But I just -- I want to reiterate, GPS will become who we are and how we operate. And it will allow and enable us to go very deep in the organization and drive accountability. And it's part of our journey around the continuous improvement model and how we need to continue to improve our say-do ratio. And it's an area that we'll continue to update as we go throughout the year.

    我只想說——我同意。這是對市場的一種看法。這是我們審慎的運作方式。但我只想重申,GPS 將成為我們存在的意義和運作方式。這將使我們能夠深入組織內部,推動問責制。這是我們持續改善模式之旅的一部分,也是我們需要不斷提升言行比的一部分。我們將全年持續更新這方面的資訊。

  • Operator

    Operator

  • And at this time, I will now hand the call back over to Andrew for some final closing comments.

    現在,我將把電話交還給安德魯,讓他做一些最後的總結發言。

  • Andrew Hider - Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director

    Andrew Hider - Chief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director

  • Yeah, thanks, operator. Look, in closing, we're not where we want to be, but we're confronting our challenges head on and taking deliberate steps each day to better position Baxter for the long term. I'm energized by the opportunities ahead, driven by the essential role Baxter plays in patient care and our mission-driven team that is committed to driving stronger and performing over a long period of time. Thank you very much. Stay safe, and goodbye for now.

    好的,謝謝接線生。最後,我們還沒有達到我們想要的目標,但我們正在迎難而上,每天都在採取實際措施,讓百特公司能更好地為長遠發展做好準備。未來的機會令我充滿活力,百特在病患照護中發揮著至關重要的作用,我們以使命為導向的團隊致力於在長期內不斷進步和取得更大成就。非常感謝。注意安全,再見。

  • Operator

    Operator

  • Ladies and gentlemen, this concludes today's conference call with Baxter International. Thank you for participating.

    女士們、先生們,今天與百特國際的電話會議到此結束。感謝您的參與。